Gilead Sciences Inc (NAS:GILD)
$ 64.6 -0.34 (-0.52%) Market Cap: 80.48 Bil Enterprise Value: 98.68 Bil PE Ratio: 179.39 PB Ratio: 4.61 GF Score: 74/100

Gilead Sciences Inc at Raymond James Institutional Investors Conference Transcript

Mar 08, 2022 / 06:05PM GMT
Release Date Price: $59.54 (-1.19%)
Steven James Seedhouse
Raymond James & Associates, Inc., Research Division - Research Analyst

Well, great. Well, welcome, everyone, to our next session at the Raymond James 43rd Annual Institutional Investors Conference. I'm Steve Seedhouse, biotech analyst at Raymond James. Really my pleasure to welcome Gilead to the conference this year. Gilead, of course, one of the largest well-known biotechnology companies in the world, developing and marketing therapeutics for infectious disease, cancer and other diseases.

Privileged to be joined for a fireside chat by CFO, Andrew Dickinson, Andy joined Gilead in 2016. Prior to his current role, CFO, served as Head of the company's Corporate Development and Strategy Group, in that role drove all of Gilead's licensing partnership and acquisition transactions and guided investment into new areas.

So Andy, welcome.

Andrew D. Dickinson;Steven James Seedhouse
Gilead Sciences, Inc. - Executive VP & CFO;Raymond James & Associates, Inc., Research

Thank you.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot